HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibitory effect of drugs used in the treatment of Parkinson's disease on plasma monoamine oxidase activity.

Abstract
The plasma amine oxidase (benzylamine oxidase, BzAO) of patients with Parkinson's disease is sometimes decreased in activity, when compared to normal controls. This is the result of therapy with DOPA decarboxylase inhibitors. The Authors suggest that complications due to prolonged therapy with these drugs may be, at least in part, the result of an interference with BzAO capacity to catabolize circulating amines.
AuthorsH Coelho, M Azevedo, C Manso
JournalJournal of neural transmission (J Neural Transm) Vol. 61 Issue 3-4 Pg. 271-7 ( 1985) Austria
PMID3989525 (Publication Type: Journal Article)
Chemical References
  • Hydrazines
  • Isoenzymes
  • Monoamine Oxidase Inhibitors
  • Benserazide
  • Benzylamine Oxidase
  • Monoamine Oxidase
  • Carbidopa
Topics
  • Adult
  • Aged
  • Benserazide (administration & dosage, pharmacology)
  • Benzylamine Oxidase (antagonists & inhibitors, blood)
  • Carbidopa (administration & dosage, adverse effects)
  • Female
  • Humans
  • Hydrazines (pharmacology)
  • Isoenzymes (blood)
  • Male
  • Middle Aged
  • Monoamine Oxidase (blood)
  • Monoamine Oxidase Inhibitors
  • Parkinson Disease (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: